PROTAC ERα Degrader-4
CAT:
804-HY-149295-02
Size:
5 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No

PROTAC ERα Degrader-4
- CAS Number: 2521299-80-7
- UNSPSC Description: PROTAC ERα Degrader-4 is a highly potent and selectivePROTAC ERα degrader (Ki: 5.08 μM). PROTAC ERα Degrader-4 contains OBHSAs, linker and E3 ligase ligands. PROTAC ERα Degrader-4 shows excellent cell inhibitory and ERα degradation activity against Tamoxifen-sensitive and -resistant ER+ breast cancer (BC) cells and ERα-mutated BC cells. PROTAC ERα Degrader-4 can induce apoptosis and can be used for cancer research.
- Target Antigen: Apoptosis; Estrogen Receptor/ERR; PROTACs
- Type: Reference compound
- Related Pathways: Apoptosis;PROTAC;Vitamin D Related/Nuclear Receptor
- Applications: Cancer-programmed cell death
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/protac-erα-degrader-4.html
- Solubility: 10 mM in DMSO
- Smiles: CC1=C(C2=CC=C(C=C2)[C@@H](NC([C@@H]3C[C@H](CN3C([C@@H](NC(CCCCCOC4=CC=C(C=C4)N(CC(F)(F)F)S(C5C[C@@H]6C(C7=CC=C(C=C7)O)=C([C@H]5O6)C8=CC=C(C=C8)O)(=O)=O)=O)C(C)(C)C)=O)O)=O)C)SC=N1
- Molecular Weight: 1074.23
- References & Citations: [1]Xie B, et.al. Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer In Vitro and In Vivo. J Med Chem. 2023 May 25;66(10):6631-6651.
- Shipping Conditions: Blue Ice
- Clinical Information: No Development Reported